Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista da Associação Médica Brasileira (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100025 |
Resumo: | OBJECTIVE: Methylprednisolone pulses are used in a variety of disease conditions, both for acute and chronic therapy. Although well tolerated, they increase glucose levels in both non-diabetic and diabetic patients. They may also be considered a significant risk for acute metabolic alterations. The purpose of this report is to determine the metabolic changes in blood glucose levels in non-diabetic patients receiving methylprednisolone pulses and identify the presence of predictive factors for its development. METHODS: Observational, prospective study in 50 non-diabetic patients receiving 1 g intravenous methylprednisolone pulses for three consecutive days as an indication for diverse autoimmune disorders. Demographic, anthropometric, and metabolic variables were analyzed, and glucose, insulin and C-peptide levels after each steroid pulse were identified. Different variables and the magnitude of hyperglycemia were analyzed using Pearson's correlation. RESULTS: 50 patients were included, predominantly women (66%, n = 33). The average age was 41 ± 14 years with a BMI of 26 ± 3 kg/m². Baseline glucose was 83 ± 10 mg/dL. After each steroid pulse, glucose increased to 140 ± 28, 160 ± 38 and 183 ± 44, respectively (p < 0.001). C-peptide and insulin concentrations increased significantly (p < 0.001). The prevalence of fasting hyperglycemia after each pulse was 68%, 94% and 98%, respectively. We found no correlation between the magnitude of hyperglycemia and the studied variables. CONCLUSION: Methylprednisolone pulses produced significant increases in fasting glucose in most patients without diabetes. Further studies are needed to define its role in long-term consequences. |
id |
AMB-1_7f50be6f6f04c8cabd41d2a1c1fff5b9 |
---|---|
oai_identifier_str |
oai:scielo:S0104-42302012000100025 |
network_acronym_str |
AMB-1 |
network_name_str |
Revista da Associação Médica Brasileira (Online) |
repository_id_str |
|
spelling |
Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulsesMethylprednisolonediabetes mellitushyperglycemiaOBJECTIVE: Methylprednisolone pulses are used in a variety of disease conditions, both for acute and chronic therapy. Although well tolerated, they increase glucose levels in both non-diabetic and diabetic patients. They may also be considered a significant risk for acute metabolic alterations. The purpose of this report is to determine the metabolic changes in blood glucose levels in non-diabetic patients receiving methylprednisolone pulses and identify the presence of predictive factors for its development. METHODS: Observational, prospective study in 50 non-diabetic patients receiving 1 g intravenous methylprednisolone pulses for three consecutive days as an indication for diverse autoimmune disorders. Demographic, anthropometric, and metabolic variables were analyzed, and glucose, insulin and C-peptide levels after each steroid pulse were identified. Different variables and the magnitude of hyperglycemia were analyzed using Pearson's correlation. RESULTS: 50 patients were included, predominantly women (66%, n = 33). The average age was 41 ± 14 years with a BMI of 26 ± 3 kg/m². Baseline glucose was 83 ± 10 mg/dL. After each steroid pulse, glucose increased to 140 ± 28, 160 ± 38 and 183 ± 44, respectively (p < 0.001). C-peptide and insulin concentrations increased significantly (p < 0.001). The prevalence of fasting hyperglycemia after each pulse was 68%, 94% and 98%, respectively. We found no correlation between the magnitude of hyperglycemia and the studied variables. CONCLUSION: Methylprednisolone pulses produced significant increases in fasting glucose in most patients without diabetes. Further studies are needed to define its role in long-term consequences.Associação Médica Brasileira2012-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100025Revista da Associação Médica Brasileira v.58 n.1 2012reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/S0104-42302012000100025info:eu-repo/semantics/openAccessTamez Perez,Hector EloyGómez de Ossio,María DoloresQuintanilla Flores,Dania LizetHernández Coria,Mayra IvonneTamez Peña,Alejandra LorenaCuz Pérez,Gissén JazmínProskauer Peña,Stephanie Lissetteeng2012-02-28T00:00:00Zoai:scielo:S0104-42302012000100025Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2012-02-28T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false |
dc.title.none.fl_str_mv |
Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses |
title |
Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses |
spellingShingle |
Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses Tamez Perez,Hector Eloy Methylprednisolone diabetes mellitus hyperglycemia |
title_short |
Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses |
title_full |
Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses |
title_fullStr |
Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses |
title_full_unstemmed |
Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses |
title_sort |
Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses |
author |
Tamez Perez,Hector Eloy |
author_facet |
Tamez Perez,Hector Eloy Gómez de Ossio,María Dolores Quintanilla Flores,Dania Lizet Hernández Coria,Mayra Ivonne Tamez Peña,Alejandra Lorena Cuz Pérez,Gissén Jazmín Proskauer Peña,Stephanie Lissette |
author_role |
author |
author2 |
Gómez de Ossio,María Dolores Quintanilla Flores,Dania Lizet Hernández Coria,Mayra Ivonne Tamez Peña,Alejandra Lorena Cuz Pérez,Gissén Jazmín Proskauer Peña,Stephanie Lissette |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Tamez Perez,Hector Eloy Gómez de Ossio,María Dolores Quintanilla Flores,Dania Lizet Hernández Coria,Mayra Ivonne Tamez Peña,Alejandra Lorena Cuz Pérez,Gissén Jazmín Proskauer Peña,Stephanie Lissette |
dc.subject.por.fl_str_mv |
Methylprednisolone diabetes mellitus hyperglycemia |
topic |
Methylprednisolone diabetes mellitus hyperglycemia |
description |
OBJECTIVE: Methylprednisolone pulses are used in a variety of disease conditions, both for acute and chronic therapy. Although well tolerated, they increase glucose levels in both non-diabetic and diabetic patients. They may also be considered a significant risk for acute metabolic alterations. The purpose of this report is to determine the metabolic changes in blood glucose levels in non-diabetic patients receiving methylprednisolone pulses and identify the presence of predictive factors for its development. METHODS: Observational, prospective study in 50 non-diabetic patients receiving 1 g intravenous methylprednisolone pulses for three consecutive days as an indication for diverse autoimmune disorders. Demographic, anthropometric, and metabolic variables were analyzed, and glucose, insulin and C-peptide levels after each steroid pulse were identified. Different variables and the magnitude of hyperglycemia were analyzed using Pearson's correlation. RESULTS: 50 patients were included, predominantly women (66%, n = 33). The average age was 41 ± 14 years with a BMI of 26 ± 3 kg/m². Baseline glucose was 83 ± 10 mg/dL. After each steroid pulse, glucose increased to 140 ± 28, 160 ± 38 and 183 ± 44, respectively (p < 0.001). C-peptide and insulin concentrations increased significantly (p < 0.001). The prevalence of fasting hyperglycemia after each pulse was 68%, 94% and 98%, respectively. We found no correlation between the magnitude of hyperglycemia and the studied variables. CONCLUSION: Methylprednisolone pulses produced significant increases in fasting glucose in most patients without diabetes. Further studies are needed to define its role in long-term consequences. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-02-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100025 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100025 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0104-42302012000100025 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
Revista da Associação Médica Brasileira v.58 n.1 2012 reponame:Revista da Associação Médica Brasileira (Online) instname:Associação Médica Brasileira (AMB) instacron:AMB |
instname_str |
Associação Médica Brasileira (AMB) |
instacron_str |
AMB |
institution |
AMB |
reponame_str |
Revista da Associação Médica Brasileira (Online) |
collection |
Revista da Associação Médica Brasileira (Online) |
repository.name.fl_str_mv |
Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB) |
repository.mail.fl_str_mv |
||ramb@amb.org.br |
_version_ |
1754212830268096512 |